Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.

Cheng DD, Zhang HZ, Yuan JQ, Li SJ, Yang QC, Fan CY.

Oncotarget. 2017 Apr 18;8(16):26380-26393. doi: 10.18632/oncotarget.15474.

2.

Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-9. doi: 10.1093/jnci/djw231.

PMID:
28376202
3.

Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.

Gilbert-Ross M, Konen J, Koo J, Shupe J, Robinson BS, Wiles WG 4th, Huang C, Martin WD, Behera M, Smith GH, Hill CE, Rossi MR, Sica GL, Rupji M, Chen Z, Kowalski J, Kasinski AL, Ramalingam SS, Fu H, Khuri FR, Zhou W, Marcus AI.

JCI Insight. 2017 Mar 9;2(5):e90487. doi: 10.1172/jci.insight.90487.

4.

Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.

Yadavalli S, Jayaram S, Manda SS, Madugundu AK, Nayakanti DS, Tan TZ, Bhat R, Rangarajan A, Chatterjee A, Gowda H, Thiery JP, Kumar P.

Sci Rep. 2017 Mar 6;7:43710. doi: 10.1038/srep43710.

5.

Non-small cell lung cancer: the era of targeted therapy.

Antonoff MB, D'Cunha J.

Lung Cancer (Auckl). 2012 Jul 2;3:31-41. doi: 10.2147/LCTT.S16442. eCollection 2012. Review.

6.

The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.

Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S, Webber P, McMillan E, Rusnak L, Pham C, Chen X, Mo X, Revennaugh B, Zhou W, Marcus A, Harati S, Chen X, Johns MA, White MA, Moreno C, Cooper LA, Du Y, Khuri FR, Fu H.

Nat Commun. 2017 Feb 16;8:14356. doi: 10.1038/ncomms14356.

7.

Coordinated cell motility is regulated by a combination of LKB1 farnesylation and kinase activity.

Wilkinson S, Hou Y, Zoine JT, Saltz J, Zhang C, Chen Z, Cooper LA, Marcus AI.

Sci Rep. 2017 Jan 19;7:40929. doi: 10.1038/srep40929.

8.

Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs.

Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, Horng W, Fridlender G, Albelda SM, Fridlender ZG.

Oncoimmunology. 2016 Sep 13;5(11):e1232221. doi: 10.1080/2162402X.2016.1232221. eCollection 2016.

PMID:
27999744
9.

LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.

Wang YS, Chen J, Cui F, Wang H, Wang S, Hang W, Zeng Q, Quan CS, Zhai YX, Wang JW, Shen XF, Jian YP, Zhao RX, Werle KD, Cui R, Liang J, Li YL, Xu ZX.

Oncotarget. 2016 Nov 8;7(45):73389-73401. doi: 10.18632/oncotarget.12334.

10.

LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism.

Zeng Q, Chen J, Li Y, Werle KD, Zhao RX, Quan CS, Wang YS, Zhai YX, Wang JW, Youssef M, Cui R, Liang J, Genovese N, Chow LT, Li YL, Xu ZX.

Oncogene. 2017 Mar 2;36(9):1245-1255. doi: 10.1038/onc.2016.290. Epub 2016 Aug 22.

11.

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.

Monica V, Lo Iacono M, Bracco E, Busso S, Di Blasio L, Primo L, Peracino B, Papotti M, Scagliotti G.

Oncotarget. 2016 Nov 22;7(47):76577-76589. doi: 10.18632/oncotarget.10428.

12.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK.

Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190. Epub 2016 Jun 23.

13.

Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients.

Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills GB, Shu Y, Li L, Liang H.

Cancer Cell. 2016 May 9;29(5):711-22. doi: 10.1016/j.ccell.2016.04.001.

14.

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.

Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S.

Cancer Discov. 2016 Jul;6(7):754-69. doi: 10.1158/2159-8290.CD-15-1377. Epub 2016 May 6.

15.

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.

Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L.

J Clin Invest. 2016 Jun 1;126(6):2267-79. doi: 10.1172/JCI85250. Epub 2016 May 3.

16.

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).

Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH.

Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.

17.

A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD.

J Thorac Oncol. 2016 Jun;11(6):838-49. doi: 10.1016/j.jtho.2016.02.009. Epub 2016 Feb 23.

18.

LKB1 kinase-dependent and -independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion.

Konen J, Wilkinson S, Lee B, Fu H, Zhou W, Jiang Y, Marcus AI.

Mol Biol Cell. 2016 Apr 1;27(7):1069-84. doi: 10.1091/mbc.E15-08-0569. Epub 2016 Feb 10.

19.

The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution.

Wang GZ, Cheng X, Zhou B, Wen ZS, Huang YC, Chen HB, Li GF, Huang ZL, Zhou YC, Feng L, Wei MM, Qu LW, Cao Y, Zhou GB.

Elife. 2015 Nov 13;4. pii: e09419. doi: 10.7554/eLife.09419.

20.

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.

Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA.

Oncogene. 2016 Jun 16;35(24):3209-16. doi: 10.1038/onc.2015.375. Epub 2015 Oct 19.

Supplemental Content

Support Center